In this issue:
Genetic abnormalities in myelodysplasia and secondary AML: post-SCT outcomes
Therapy responses at the leukaemic subclone level in AML
New assay for proliferation signature in MCL, applicable to FFPE biopsies
Idarubicin dose escalation during consolidation for AML
Pacritinib for myelofibrosis irrespective of baseline cytopenias
TMTV affects rituximab exposure and predicts DLBCL outcomes
Ublituximab for rituximab-relapsed/refractory B-cell NHL and CLL
Extracorporeal photopheresis for CTCL and GVHD: an update
Trends in haemophilia prophylaxis use, bleeding rates and joint outcomes
Please login below to download this issue (PDF)